华东医药表示，本次注射用HDM2024美国临床试验获批，是该款产品研发进程中的又一重要进展，将进一步提升公司在肿瘤治疗领域的核心竞争力。根据美国药品注册相关的法律法规要求，药物在获得临床试验批准通知书后，尚需开展一系列临床试验并经美国FDA批准后方可上市。此次获得临床试验批准，对公司近期业绩不会产生重大影响。药品研发存在投入大、周期长、风险高等特点，临床试验进度及结果、未来产品市场竞争形势均存在诸 ...

Data show T-DXd improves invasive disease-free survival and reduces the risk of distant recurrence in early HER2-positive breast cancer.

Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard ...

患者，女性，54岁，2017年10月因“发现左乳肿块2周”就诊。 现病史：患者2周前无明显诱因发现左乳肿块，无外伤史，无疼痛不适，无乳头溢液，无皮肤红肿破溃，我院B超提示“左乳多发结节，较大结节BI-RADS 4B类；双侧腋下未见明显肿大淋巴结”。 既往史 ...

Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care ...

Sivelestat significantly reduced the incidence of postoperative ARDS, lowered 90-day mortality, and suppressed inflammatory biomarkers linked to lung injury.

Peter Staley at CROI 2026 on defending 45 years of HIV progress: how clinicians, payers, and advocates can resist—quietly or publicly—and why it matters.